Influence of female sex hormone change during menstrual cycle on propofol pharmacokinetics and pharmacodynamics
Not Applicable
- Conditions
- Patients planning on getting surgery under general anesthesia
- Registration Number
- JPRN-UMIN000018109
- Lead Sponsor
- ational Defense Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 90
Inclusion Criteria
Not provided
Exclusion Criteria
1.Obesity 2.Pregnant women and nursing mothers 3.Postmenopausal women 4.Patients with severe liver or kidney disorder 5.Patients with neurological disorder 6.Patients taking psychotropic drugs orally 7.Patients with hypersensitivity to propofol 8.Patients who attending physicians consider to be inappropriate due to other reasons mentioned above
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method preparation of pharmacokinetic/pharmacodynamic model on female surgical patients
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How do estrogen and progesterone fluctuations during the menstrual cycle alter propofol's CYP2B6/CYP2C9 metabolism in surgical patients?
What comparative efficacy data exists for propofol versus sevoflurane/fentanyl in female anesthesia during follicular vs. luteal phases?
Which hormone-specific biomarkers (estradiol, progesterone) predict propofol sedation depth and recovery time in perioperative settings?
What adverse event profiles emerge from propofol use in relation to menstrual cycle phase and sex hormone receptor expression?
How do sex hormone dynamics during the menstrual cycle influence propofol's pharmacodynamics compared to ketamine/etomidate in women?